Novavax, Inc.

NASDAQ:NVAX   3:59:59 PM EDT
87.34
-5.79 (-6.22%)
4:35:09 PM EDT: $87.80 +0.46 (+0.53%)
Products, Regulatory

Novavax Initiates Phase 3 Efficacy Trial Of COVID-19 Vaccine In The United Kingdom

Published: 09/24/2020 20:40 GMT
Novavax Inc (NVAX) - Novavax Initiates Phase 3 Efficacy Trial of Covid-19 Vaccine in the United Kingdom.
Novavax Inc - Clinical Trial to Enroll Up to 10,000 Volunteers Across Uk to Assess Whether Nvx-cov2373 is Effective in Prevention of Covid-19.
Novavax - Trial is Expected to Enroll and Immunize Up to 10,000 Individuals Between 18-84 Yrs of Age Over Next Four to Six Weeks.
Novavax Inc - Phase 3 Efficacy Trial of Covid-19 Vaccine in United Kingdom Designed to Enroll at Least 25 Percent of Participants Over Age of 65.
Novavax Inc - Up to 400 Participants Will Also Receive a Licensed Seasonal Influenza Vaccine As Part of a Co-administration Sub-study.
Novavax Inc - Has Continued to Scale-up Its Manufacturing Capacity, Currently at Up to 2 Billion Annualized Doses.
Novavax Inc - Trial of Covid-19 Vaccine in Uk to Prioritize Groups That Are Most Affected by Covid-19, Including Racial and Ethnic Minorities.
Novavax Inc - Phase 3 Efficacy Trial of Covid-19 Trial Has Two Primary Endpoints.
Novavax Inc - Interim Analysis Will Be Performed When 67% of Desired Number of Cases Has Been Reached.